about
sameAs
Charting the molecular network of the drug target Bcr-Ablc-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's diseaseThe DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune responseStructural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activationThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLStructural basis for the autoinhibition of c-Abl tyrosine kinaseThe structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domainTargeting the SH2-Kinase Interface in Bcr-Abl Inhibits LeukemogenesisDissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domainsCrystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activityOrganization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.The central domain of the matrix protein of HIV-1: influence on protein structure and virus infectivity.Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells.Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.Regulation of the c-Abl and Bcr-Abl tyrosine kinases.The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibAlkaline phosphatase-fused repebody as a new format of immuno-reagent for an immunoassay.Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic AnalysisStructure, regulation, signaling, and targeting of abl kinases in cancer.Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasisAllosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase InterfaceNilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.Mechanisms of resistance to BCR-ABL and other kinase inhibitors.Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.HRD Motif as the Central Hub of the Signaling Network for Activation Loop Autophosphorylation in Abl Kinase.BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.A myristoyl/phosphotyrosine switch regulates c-Abl.The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia.Cell biology: a key driver of therapeutic innovation.Kinase-templated abiotic reaction.Single-molecule kinetic analysis of HP1-chromatin binding reveals a dynamic network of histone modification and DNA interactions.Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable".
P50
Q24317707-A3734D71-8617-48D6-8C88-6843E327CD63Q24318974-B787DA02-A0E0-45A6-9F55-90E99C92EE64Q24336273-6A0C8F18-6DF6-417D-9958-839B6AC0356DQ24648477-8A4492CA-8F8C-4CD8-B45A-A3AFD9BB6A67Q26866312-F298C60A-42FA-4DAD-81C1-16083C24133FQ27640773-FB489052-48B3-4D81-B010-86187B99625AQ27653890-830B8CA6-6708-4991-98E8-1A05490F1248Q27660385-F2E7D725-6B24-45D9-8029-0076DBC82C4CQ27675049-780C6BAA-F2F7-4238-9E36-97EF2C9DF4EAQ27679810-829ED39C-485B-4E1E-974E-5523AE0E3044Q27698513-5F386BF9-4214-4501-96F2-4E64F32918F5Q30159870-698C855A-41D5-4164-9C4A-ED172A02C04AQ30341481-9BA38E96-D0B7-4BB6-A9E8-6B99673DA3C2Q33637065-0A030A4A-7908-4E98-9992-75AB5E5DCB38Q33899740-03A48F28-7EF0-48EC-829C-0766E3B7DCBBQ34576212-18F9A6F8-44B5-4B0E-AFF8-1A494A861DAAQ34768779-C71B11D1-C931-49C6-A553-912D58C16CDAQ35621355-6C74B819-6708-4FC4-A854-D3A62EB0E494Q35925610-4118F21D-3779-4B42-AEDF-CCE2D65C6E52Q36212872-2A1F5646-8EDC-4E3E-9B76-6C60F17FACDEQ36437173-0AB3203A-F136-4B5D-9D39-364F64385E68Q36443429-ECBE3BE3-3241-4493-BEC6-62F2920E5794Q36851400-1CE3842D-EBDB-4999-ADEE-4692887ABED7Q36852720-FB3E0191-34F9-4C3A-AE88-A52E80702AFBQ36884733-9EAADB07-6304-418C-BD5B-562791482B33Q37929403-54C06FBC-AB87-4B5F-91DD-7D5CC523BD62Q38070638-7443E027-45E8-42B8-9550-9CEDDA5AB364Q38296973-2CE010A7-BC26-403E-A14A-68886BF8C454Q39122858-DAEA1DD6-9B16-4F4C-9909-04071575EC0EQ39342198-2A6A0612-C8CF-4498-880B-66AAC4F9DA85Q39404871-A26FBD5D-A5C6-4FB0-995E-5823EBA7AEF6Q39911338-0FDF047B-3579-4495-972F-A128F2B0696FQ40144730-9B8398A1-D9CD-4975-B012-80551F612263Q40401088-CE3273AD-9E03-494B-BFC5-41A573E68B30Q40661872-18B76D5C-153B-4651-8512-127F55B42073Q41129829-E3BD52C5-558E-4EAF-9E32-53F37C643DBEQ41265920-CBEF113B-DBEF-4FC9-9340-EE8E65A5F938Q42160458-D6B1C844-FF93-43EF-B19A-3BFD8A0F3908Q42796150-A9A2113F-8135-45D5-9360-B09991BB7CF3Q43057177-9334E14F-32FC-4C04-AD30-5F59D0F7F19E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Oliver Hantschel
@ast
Oliver Hantschel
@en
Oliver Hantschel
@es
Oliver Hantschel
@nl
Oliver Hantschel
@sl
type
label
Oliver Hantschel
@ast
Oliver Hantschel
@en
Oliver Hantschel
@es
Oliver Hantschel
@nl
Oliver Hantschel
@sl
prefLabel
Oliver Hantschel
@ast
Oliver Hantschel
@en
Oliver Hantschel
@es
Oliver Hantschel
@nl
Oliver Hantschel
@sl
P1053
H-4705-2013
P106
P1153
23060009700
P21
P31
P3829
P496
0000-0001-8569-8169